These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15590164)

  • 21. Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: a critical review.
    van der Wielen GJ; Mulhall JP; Incrocci L
    Radiother Oncol; 2007 Aug; 84(2):107-13. PubMed ID: 17707936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
    Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced radiation tolerance of penile structures associated with dose-escalated hypofractionated prostate radiotherapy.
    McDonald AM; Baker CB; Shekar K; Popple RA; Clark GM; Yang ES; Jacob R; Kim RY; Fiveash JB
    Urology; 2014 Dec; 84(6):1383-7. PubMed ID: 25440987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy.
    Belderbos JS; Heemsbergen WD; De Jaeger K; Baas P; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):126-34. PubMed ID: 16904518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy.
    Hong TS; Tomé WA; Jaradat H; Raisbeck BM; Ritter MA
    Acta Oncol; 2006; 45(6):717-27. PubMed ID: 16938815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.
    Wang-Chesebro A; Xia P; Coleman J; Akazawa C; Roach M
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):654-62. PubMed ID: 17011444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of late rectal toxicity from conventional versus three-dimensional conformal radiotherapy for prostate cancer: analysis of clinical and dosimetric factors.
    Lee CM; Lee RJ; Handrahan DL; Sause WT
    Urology; 2005 Jan; 65(1):114-9. PubMed ID: 15667875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sexual function after three-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial.
    van der Wielen GJ; van Putten WL; Incrocci L
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):479-84. PubMed ID: 17331667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An analysis of erectile function after intensity modulated radiation therapy for localized prostate carcinoma.
    Brown MW; Brooks JP; Albert PS; Poggi MM
    Prostate Cancer Prostatic Dis; 2007; 10(2):189-93. PubMed ID: 17189954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. There is no correlation between erectile dysfunction and dose to penile bulb and neurovascular bundles following real-time low-dose-rate prostate brachytherapy.
    Solan AN; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1468-74. PubMed ID: 18922652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement.
    Jacob R; Hanlon AL; Horwitz EM; Movsas B; Uzzo RG; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):695-701. PubMed ID: 15708247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: preliminary results of a prospective phase II study.
    Maluta S; Dall'Oglio S; Romano M; Marciai N; Pioli F; Giri MG; Benecchi PL; Comunale L; Porcaro AB
    Int J Hyperthermia; 2007 Aug; 23(5):451-6. PubMed ID: 17701536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II trial for the optimisation of treatment position in the radiation therapy of prostate cancer.
    O'Neill L; Armstrong J; Buckney S; Assiri M; Cannon M; Holmberg O
    Radiother Oncol; 2008 Jul; 88(1):61-6. PubMed ID: 18453021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment.
    Gauthier I; Carrier JF; Béliveau-Nadeau D; Fortin B; Taussky D
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1128-33. PubMed ID: 19147306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
    Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
    Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies.
    Ben-Josef E; Normolle D; Ensminger WD; Walker S; Tatro D; Ten Haken RK; Knol J; Dawson LA; Pan C; Lawrence TS
    J Clin Oncol; 2005 Dec; 23(34):8739-47. PubMed ID: 16314634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II feasibility study of high-dose radiotherapy for prostate cancer using proton boost therapy: first clinical trial of proton beam therapy for prostate cancer in Japan.
    Nihei K; Ogino T; Ishikura S; Kawashima M; Nishimura H; Arahira S; Onozawa M
    Jpn J Clin Oncol; 2005 Dec; 35(12):745-52. PubMed ID: 16314345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel prostate brachytherapy technique: improved dosimetric and clinical outcome.
    Nobes JP; Khaksar SJ; Hawkins MA; Cunningham MJ; Langley SE; Laing RW
    Radiother Oncol; 2008 Jul; 88(1):121-6. PubMed ID: 18499289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.